ArticleJournal of the American Heart Association2013
Lack of reduction of left ventricular mass in treated hypertension: the strong heart study.
Article in Journal of the American Heart Association, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 91 citations in OpenAlex.
- Preclinical cardiac organ damage during statin treatment in patients with inflammatory joint diseases: the RORA-AS statin intervention study.Rheumatology (Oxford, England) · 2020Trial
- Influence of hypertension and global or abdominal obesity on left ventricular hypertrophy: A cross-sectional study.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- The Pandora's Box of Hypertensive Heart Disease in Women.JACC. Advances · 2024Article
- The use of echocardiography compared to electrocardiogram when screening for left ventricular hypertrophy in hypertensive patients: A cross-sectional study.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Electrocardiographic tracking of left ventricular hypertrophy in hypertension: incidence and prognostic outcomes from the SPRINT trial.Clinical hypertension · 2024Article
- Age-dependent implications of left ventricular hypertrophy regression in patients with hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Phosphate in Cardiovascular Disease: From New Insights Into Molecular Mechanisms to Clinical Implications.Arteriosclerosis, thrombosis, and vascular biology · 2024Review
- The cardiovascular changes underlying a low cardiac output with exercise in patients with type 2 diabetes mellitus.Frontiers in physiology · 2024Review
- Sex, gender, and subclinical hypertensiveorgan damage-heart.Journal of human hypertension · 2023Review
- Association of High Normal Body Weight in Youths With Risk of Hypertension.JAMA network open · 2023Article
- Hypertensive heart disease: risk factors, complications and mechanisms.Frontiers in cardiovascular medicine · 2023Review
- Sex differences in arterial hypertension.European heart journal · 2022Review
- Cardiovascular Disease Risk Reduction and Body Mass Index.Current hypertension reports · 2022Review
- High incidence of hypertension-mediated organ damage in a series of Chinese patients with 17α-hydroxylase deficiency.Endocrine · 2022Article
- Carotid Atherosclerosis Predicts Blood Pressure Control in Patients With Hypertension: The Campania Salute Network Registry.Journal of the American Heart Association · 2022Article
- Prognostic implication of left ventricular hypertrophy regression after antihypertensive therapy in patients with hypertension.Frontiers in cardiovascular medicine · 2022Article
- Sex differences in hypertension. Do we need a sex-specific guideline?Frontiers in cardiovascular medicine · 2022Review
- Left Ventricular Measurements and Strain in Pediatric Patients Evaluated for Systemic Hypertension and the Effect of Adequate Anti-hypertensive Treatment.Pediatric cardiology · 2022Article
- Prognostic Significance of Echocardiographic Measures of Cardiac Remodeling in the Community.Current cardiology reports · 2021Review
- Hypertension in Women: Should There be a Sex-specific Threshold?European cardiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundHypertensive left ventricular mass (LVM) is expected to decrease during antihypertensive therapy, based on results of clinical trials. METHODS AND
resultsWe assessed 4-year change of echocardiographic LVM in 851 hypertensive free-living participants of the Strong Heart Study (57% women, 81% treated). Variations of 5% or more of the initial systolic blood pressure (SBP) and LVM were categorized for analysis. At baseline, 23% of men and 36% of women exhibited LV hypertrophy (LVH, P<0.0001). At the follow-up, 3% of men and 10% of women had regression of LVH (P<0.0001 between genders); 14% of men and 15% of women, free of baseline LVH, developed LVH. There was an increase in LVM over time, more in men than in women (P<0.001). Participants whose LVM did not decrease had similar baseline SBP and diastolic BP, but higher body mass index (BMI), waist/hip ratio, heart rate (all P<0.008), and urinary albumin/creatinine excretion (P<0.001) than those whose LVM decreased. After adjusting for field center, initial LVM index, target BP, and kinship degree, lack of decrease in LVM was predicted by higher baseline BMI and urinary albumin/creatinine excretion, independently of classes of antihypertensive medications, and significant effects of older age, male gender, and percentage increase in BP over time. Similar findings were obtained in the subpopulation (n=526) with normal BP at follow-up.
conclusionsIn a free-living population, higher BMI is associated with less reduction of hypertensive LVH; lack of reduction of LVM is independent of BP control and of types of antihypertensive treatment, but is associated with renal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.